San Diego, May 21, 2020 – Origami Therapeutics has been selected as a finalist in the forthcoming Digital RESI June Conference Innovation Challenge. Companies were selected on the basis of innovative technology, strong management team, clear pathway to commercialization, and other positive factors that demonstrated high growth potential. Conference attendees will be able to vote for their favorite technologies during the 3-day conference and the Top 3 winners will be announced on Wednesday, June 10. You can find a list of the finalists here.

About the RESI Conference Series

The Redefining Early Stage Investments (RESI) conference series was created by Life Science Nation (LSN) to bring together startups with early-stage investors and strategic channel partners. The goal was to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. Conferences take place in various locations throughout the year, with the next one scheduled to occur digitally from June 9 – 10, 2020.

About Origami Therapeutics

Origami is generating a pipeline of small molecule therapeutics that prevent or delay the onset and the progression of neurodegenerative diseases by targeting the underlying genetic cause of disease. Currently, they are selecting the optimal protein degrader molecule to advance into preclinical testing for Huntington’s disease, a devastating fatal disease that strikes at the prime of life. Origami’s core technology should be applicable to multiple neurological disorders where the proximate cause of the disease is a misfolded protein. These include AD, PD, ALS, frontotemporal dementia, Lewy body diseases, and other poly Q diseases. For more information, please visit